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Abstract
This guideline presents reference limits for use in echocardiographic practice, updating 
previous guidance from the British Society of Echocardiography. The rationale for change 
is discussed, in addition to how the reference intervals were defined and the current 
limitations to their use. The importance of interpretation of echocardiographic parameters 
within the clinical context is explored, as is grading of abnormality. Each of the following 
echo parameters are discussed and updated in turn: left ventricular linear dimensions and 
LV mass; left ventricular volumes; left ventricular ejection fraction; left atrial size; right heart 
parameters; aortic dimensions; and tissue Doppler imaging. There are several important 
conceptual changes to the assessment of the heart’s structure and function within this 
guideline. New terminology for left ventricular function and left atrial size are introduced. 
The British Society of Echocardiography has advocated a new approach to the assessment 
of the aortic root, the right heart, and clarified the optimal methodology for assessment of 
LA size. The British Society of Echocardiography has emphasized a preference to use, where 
feasible, indexed measures over absolute values for any chamber size.
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Introduction
The British Society of Echocardiography (BSE) has 
previously provided reference values and guidelines for 
chamber quantification through the provision of posters, 
pocket guides and the EchoCalc app (1, 2). These were 
based on joint publications by the American Society of 
Echocardiography (ASE) and the European Association 
of Cardiovascular Imaging (EACVI), originally published 
in 2005 (3). Newer right heart data were derived from 
guidelines published in 2010 (4). The ASE and EACVI 
subsequently updated their guidelines in 2015 (5, 6). 
Since that time further research has been published, using 
prospective data collection, on which the BSE has chosen 
to base the current recommendations upon.
For the current guidance, the BSE has chosen, in 
some instances, to deviate from the combined European 
and American guidance for our own reference intervals. 
There were several reasons for this. Principally, the BSE 
wanted to ensure that the reference ranges were derived 
from the most contemporaneous and prospectively 
acquired data; that reference ranges were derived from 
evidence that best applies to the British population; and 
finally ensure that echo guidance and cut-offs reflect 
practice within the UK. This document will outline the 
approach taken by the BSE in producing the up-to-date 
British guidelines, in addition to detailed explanatory 
notes regarding each parameter in turn. Reference 
intervals for the parameters in Table 1 are described in 
the main document and summarised in Supplementary 
Table 1 (see section on supplementary materials given 
at the end of this article). Diastolic parameters will be 
covered in a separate guideline.
The overarching objectives of this document were to:
1. Provide a simple, practical reference document and 
guide for everyday use by our members.
2. Enable appropriate interpretation of values into a 
clinically relevant report.
3. Encourage the holistic interpretation of measurements – 
no single number should define normality or pathology.
The BSE acknowledges that the changes suggested within 
this document may result in some individuals who were 
previously labelled as having an echocardiographic 
abnormality now being considered as normal (and vice 
versa). Although this can present a challenge to clinicians, 
the changes are necessary and are reflective of the current 
evidence-base. The BSE advocates that echo departments 
discuss the new reference limits with end-users, including 
cardiologists and other clinicians, to ensure that the 
changes suggested within this document are rationalised 
and that patient care is not adversely affected.
Methods
Source data
A reference interval for any echocardiographic parameter 
should be derived from a population of apparently normal 
individuals: that is to say, a group of individuals who are 
devoid of overt cardiovascular disease. It is preferred if 
individuals with multiple risk factors for cardiovascular 
disease (for example, a history of smoking or strong 
family history of coronary disease) are excluded as they 
may have as yet undiagnosed cardiac abnormalities that 
could influence the results. Once the population has 
been defined, adequate numbers of ‘normal’ participants 
across the spectrum of ages and body sizes are needed 
to ensure that the reference limits can be considered 
representative of the population at large. Studies ideally 
should be prospectively recruited and not identified from 
retrospective review of echo databases. There should be 
clear echo protocols such that each parameter is obtained 
using optimized views and best practice. In the perfect 
scenario, echo images would be reported in a core-lab, or 
dedicated independent echo-lab, to guarantee that the 
analysis of images and therefore the results are consistent. 
Finally, the individuals included in the reference data 
should reflect the population to which the ranges will 
then be applied.
The ASE/EACVI guidance from 2015 extracted echo 
data from several large databases to derive reference 
intervals (5, 6). This was commendable as it maximizes 
the number of participants, but for some parameters 
results in suboptimal methodology: for example, left 
ventricular ejection fraction (LVEF) from the apical 
four-chamber view was obtained from more than 2000 
Table 1 Echocardiographic parameters covered by the BSE 
2019 guidelines.
BSE reference intervals 2019
Linear left ventricular dimensions and LV mass
Left ventricular volumes
Left ventricular ejection fraction
Left atrial volume
Indexed right ventricular end diastolic area 
Indexed/non-indexed right atrial area
Right ventricle and right ventricular outflow tract diameter
Right ventricular fractional area change
Aortic root dimensions 
Tissue Doppler: mitral annular s′ and right ventricular s′
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individuals, but the biplane LVEF intervals were derived 
from around 500 patients. In addition, including data 
from multiple sources means that the echocardiographic 
methods for all subjects were not necessarily uniform, 
nor was quality assured with the use of a dedicated 
independent echo-lab. Finally, some results were obtained 
from a North American population and therefore may not 
be completely applicable to the British population.
Two major studies presenting useful 
echocardiographic reference intervals have been 
published subsequent to the joint ASE/EACVI guidance. 
The first of these was the Normal Reference Ranges for 
Echocardiography (NORRE) dataset which has resulted 
in multiple publications (7, 8, 9, 10). The NORRE project 
included over 700 individuals, and the study design and 
execution fulfil many of the ideal criteria outlined above. 
Participants were prospectively recruited, with pre-
defined echo protocols. All echo data were analysed by 
a core-lab, ensuring consistency of results. The included 
individuals were free from both overt cardiovascular 
disease and had low clinical probability of latent disease, 
were not taking any cardio-active medication, and all 
had lab testing for hyperglycaemia, dyslipidaemia, 
and renal function. Competitive athletes and obese 
individuals were excluded. Care was taken to ensure that 
sufficient numbers of individuals from all age categories 
were included. This study was a European collaborative 
project and therefore the results can be considered 
applicable to the UK population (7).
The second study was the EchoNormal project, a 
large meta-analysis of more than 50,000 individuals of 
differing ethnicities, obtained from over 40 different 
studies undertaken worldwide (11). After exclusions, 
more than 22,000 participants were used to define 
reference intervals. The results from the EchoNormal 
project provide a valuable insight into ethnic variation, 
and age-dependent changes of echo parameters. It is 
commendable that the cohort used in EchoNormal was 
large. However, the meta-analysis design means that the 
inclusion criteria for each of the 43 studies included were 
not necessarily identical, and the definition of ‘normal’ 
was not uniform. Echo images were analysed in the 
individual centres, and therefore consistency could not be 
guaranteed. For some parameters (including ventricular 
volumes and LVEF), data from one or more centres were 
excluded as it appeared to deviate significantly from the 
results seen elsewhere, which raises questions regarding 
validity. Finally, a large proportion of the participants 
were not European, and therefore the relevance to a UK 
population is less clear.
For these reasons, the current BSE reference intervals 
were in large part derived from the NORRE dataset.
Defining reference intervals
This guideline proposes reference intervals for 
echocardiography. These are not the same as ‘normal 
ranges’, and it is of paramount importance to understand 
the difference as this necessarily affects the way in which 
the ranges produced within this document are applied in 
day-to-day practice.
Statistical convention used throughout the literature 
states that a reference interval includes 95% of the 
normal population (Fig. 1). By definition, this excludes 
the remaining ‘normal 5%’ who appear at the upper and 
lower extreme. If the parameter in question is normally 
distributed, the 95% reference intervals can be obtained 
from the data using the mean ± 1.96 × standard deviation. 
Figure 1
The normal distribution curve. Using a 
combination of the population mean and 
standard deviation, reference limits can be 
calculated. A range of values encompassing 2 
standard deviations above and below the 
population mean includes 96.4% of all ‘normal’ 
subjects. Similarly, 3 standard deviations 
encompass 99.7% of the normal population.
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However, for almost a century, 1.96 has been rounded to 
2, which covers 95.4% of the population (12). Thus:
Upper reference limit (URL) = mean value +  
(2 × standard deviation)
Lower reference limit (LRL) = mean value –  
(2 × standard deviation)
It is a frequent misconception that if an individual parameter 
falls outside of the reference limits it should always be 
considered as abnormal. If we take the example of left 
ventricular (LV) dimensions: using the above methodology, 
it is expected that 4.6% of all normal patients will have 
values that are either above the upper reference limit or 
below the lower reference limit. In clinical practice, more 
importance is often applied to one extreme: practitioners 
may consider an increased LV size as clinically more relevant 
than a reduced size. Even in this scenario, a substantial 
number of individuals (2.3% of ‘normal’ patients) will 
have LV dimensions that are above the URL. It is therefore 
essential to interpret any value that falls outside of the 
reference limits within the clinical context, rather than 
immediately consider them as abnormal.
Similarly, it is also possible for a parameter to fall 
within the reference interval, and yet, it may not actually 
be ‘normal’ for that individual. For example, a patient may 
be noted to have an LVEF result that drops from 65 to 55% 
on sequential measurements. Although both of these LVEF 
values are within the ‘normal reference limit’, in this case, 
it is quite possible that there is an underlying pathological 
process and incipient LV systolic dysfunction. It is therefore 
of paramount importance that echocardiographic values, 
whether they are superficially normal or not, are always 
interpreted in the clinical context. If a patient has had 
previous echo studies, comparison between historical and 
contemporary findings is of significant clinical utility.
The above statistical methodology has been applied 
to the NORRE data to derive reference limits for most 
echocardiographic parameters. Detailed explanations are 
provided where the BSE has deviated from this practice.
Grading of abnormality
Once an echocardiographic value falls outside of the reference 
intervals, it is common practice to consider the parameter in 
question as being ‘mildly, moderately or severely’ abnormal 
(bearing in mind that, as discussed above, the normal/mildly 
abnormal zone will have some overlap). There are several 
reasons why this approach is useful: it helps to give an idea 
as to the magnitude of abnormality to the referring clinician, 
it may provide use in monitoring of disease progression, 
or it may provide information as to prognosis for a particular 
disease. To a clinician, an abnormality labelled as ‘severe’ 
will usually demand attention and probably treatment (i.e. 
it should not be ignored).
The partition between a ‘mild and moderate’, or 
‘moderate and severe’ abnormality can be defined in 
a number of ways. Perhaps the ideal method would be 
to define the severity of the abnormality according to 
prognostic significance: progression from mild to moderate 
to severe abnormality would be associated with clear 
impact on cardiovascular outcomes from contemporary 
studies. In reality, however, most echocardiographic 
parameters such as LVEF or LA size display a continuous 
association with survival (i.e. as the LVEF gets progressively 
lower, survival is progressively poorer (13)), and specific 
cut-offs are defined more for clinical simplicity and utility 
as opposed to being genuinely disease defining. A different 
methodology would be to define partitions according to 
clinical intervention(s) available at specific points.
Another frequent practice is to define these partitions 
as a function of the standard deviation and the mean. 
Just as the upper reference limit is usually two standard 
deviations above the mean, the partition between mild 
and moderate abnormality is defined as three standard 
deviations above the mean, and the moderate/severe 
threshold as four standard deviations above the mean. This 
is akin to paediatric cardiologist’s use of Z-scores, where 
the Z-score is the number of standard deviations from the 
mean (14). Although superficially this approach may not 
appear to have clinical relevance, it has value in providing 
information as to how frequently this magnitude of 
variation would be expected within a normal population. 
Taking the example of LV dimensions: just as 2.3% of 
normal individuals will have an LV size above the upper 
reference limit, a tiny proportion of normal individuals 
(just 0.15% of the normal population) would have 
values in the ‘moderate’ range using this methodology. 
Furthermore, essentially no normal patients would ever 
be expected to have LV dimensions in the ‘severe’ range 
(Fig. 1). This further re-iterates the clinical approach that 
once an individual parameter is close to severely abnormal 
immediate clinical attention is warranted.
Within these guidelines, grading ranges have been 
provided only where they have clinical utility.
Normal variation
Many, if not all, echocardiographic parameters vary 
according to gender, body habitus (either height, weight 
or both), ethnicity, fitness, and age. If all these variables 
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were factored into every single measurement, reporting 
times would become unreasonable, and the associated 
reference tables would be unwieldy. We have attempted 
to include as many useful variables as is practical, whilst 
maintaining the simplicity for busy echo practitioners. 
However, this has necessarily led to some compromises.
One compromise is regarding age-related variations. 
Several echocardiographic criteria (for example left and 
right ventricular size and LVEF) vary with normal aging, 
whereas others (including left and right atrial volumes 
and LV mass) do not (8). The BSE believes that it would be 
impractical to divide reference tables to account for this 
variation in some but not all parameters, particularly if 
the absolute difference is often so small as to be clinically 
insignificant. This compromise approach re-iterates the 
need to interpret values that are slightly outside the 
reference limits with caution, particularly if they are 
obtained in patients at the extremes of age.
Echocardiographic parameters are usually indexed 
according to BSA. For certain parameters, such as left 
atrial (LA) volumes, there is a wealth of evidence that 
this approach is reasonable (15, 16). For others, this 
approach may not be as useful. For example, although 
the NORRE dataset published indexed values for internal 
LV dimensions and LA diameter, neither of these are 
routinely used in clinical practice. The absolute LV 
internal diameter is a predictor of outcomes in mitral and 
aortic valve disease and is used to guide timing of surgical 
intervention (17, 18, 19). There is less data to support 
the use of indexed values in this regard. Therefore, the 
BSE has chosen to publish indexed values only for those 
parameters where there is a clear clinical indication for 
this approach.
In obese patients, caution is advised when 
interpreting indexed values, particularly as the NORRE 
database excluded individuals with a BMI >30 kg/m2. The 
metabolic demand of fatty tissue is considerably lower 
than muscle, and therefore, obesity is less likely to drive 
changes in chamber size or wall thickness. In essence, 
indexing for body surface area (BSA) when individuals are 
very overweight may result in an underestimation of the 
degree of cardiac remodelling (20).
Limitations
There are three patient cohorts in whom these reference 
tables may not be applicable. These are non-Caucasian 
individuals, athletes, and pregnant patients.
The NORRE dataset included healthy Caucasian 
volunteers only, and therefore, the values provided in 
the tables will not be as reliable in individuals of different 
ethnic origin (7). For example, there is some evidence that 
individuals of Afro-Caribbean or Asian descent differ from 
Caucasian counterparts with regards LV mass values (11).
The BSE has chosen not to include ethnicity-specific 
reference intervals for several reasons. Firstly, as we 
discussed earlier, currently available ethnicity-specific 
data from EchoNormal is not as robust as NORRE. As yet 
unpublished data from the upcoming World Alliance 
of Societies of Echocardiography Normal Values Study 
(WASE trial, presented in abstract form) suggests that in 
addition to ethnicity, the country in which an individual 
lives results in important echocardiographic variation. 
For example, individuals of Chinese descent differ 
considerably if they live in China compared to those 
that live in Europe. Similar inter-country variation was 
seen with all ethnicities. This further reinforces the BSE’s 
belief that using data obtained from China or Asia to 
derive reference intervals for individuals living in the 
UK would not be valid. Secondly, an ethnic-specific 
approach would necessarily require all sonographers to 
ask for a patient’s ethnic origin prior to undertaking an 
echo exam, which could be considered unreasonable. 
Thirdly, it is likely that individuals of mixed heritage 
would not fit solely into one dataset or another, which 
would introduce further difficulties when asking patients 
regarding their ethnicity and subsequently interpreting 
the echo findings.
Therefore, the BSE proposes that the presented 
reference tables are used for patients of all ethnicities but 
reminds sonographers to be aware of potential variation 
secondary to ethnicity. Although the available data are not 
sufficient to derive specific reference limits, the following 
could be considered within the clinical context:
 • Individuals of Afro-Caribbean descent appear to be 
very similar to Caucasians with regards LV volumes 
and function. LV mass, however, may be marginally 
higher, and therefore a ‘mild’ increase in LV mass 
should be interpreted with caution and within the 
clinical context.
 • Individuals of East Asian or Indian origin may have 
a tendency towards slightly smaller LV volumes. As 
such it is possible that LV volumes approaching the 
proposed upper reference limits may in fact be slightly 
abnormal for such ethnic groups and should be 
interpreted within the clinical context.
 • There are insufficient data to provide advice regarding 
the effects of ethnicity on LA volume or right heart size 
at this time.
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Echocardiography in athletes should also be interpreted 
with caution. Participation in competitive sport results in 
remodelling and morphological alterations of the heart, 
including increases in: LV dimensions and volumes, right 
ventricular (RV) dimensions, LV mass, and LA volumes 
(21, 22, 23, 24). The magnitude of these morphological 
alterations appears to be linked to both the volume and 
type of exercise undertaken. There is no practical or widely 
accepted way in which the effects of exercise on cardiac 
structure can be readily standardized or accounted for. 
NORRE actively excluded individuals who participated 
in competitive sport. For this reason, sonographers and 
clinicians should be cognizant of these potential influences 
when interpreting the echocardiographic findings of such 
individuals (23).
Finally, caution is advised when using these reference 
tables to interpret echocardiographic studies in pregnant 
women. Physiological cardiac adaptation during 
pregnancy includes enlargement of the left and right 
ventricles and the atria, in addition to changes in left and 
right ventricular function (25). NORRE excluded pregnant 
individuals from the study.
Timing
Timing of measurements is critical. ECG timings can vary 
with the lead used and is affected by conduction defects 
and coronary artery disease (26). The 2015 chamber 
guidelines and many textbooks have varying definitions 
(5, 6). The definitions from the EACVI/ASE/Industry Task 
Force paper on standardising deformation imaging have 
thus been adopted as follows (27).
Ventricular end systole
The timing of ventricular end systole is taken as the frame 
where the aortic valve initially closes. This coincides with 
a closure click on the pulsed-wave Doppler tracing of 
aortic valve flow. When obtaining images from the apical 
2- or 4-chamber views, end-systole is defined as the frame 
prior to mitral valve opening (5, 6). In addition, this is 
the point at which maximal volume of the LA should be 
obtained.
Ventricular end diastole
The timing of ventricular end diastole is taken as the 
frame before the mitral valve closes. Surrogates for this 
are the frame with the largest LV cavity size (diameter or 
volume), the start of the ECG QRS complex, or the ECG 
R-wave (a common trigger for analysis software).
BSE reference intervals
The following section outlines the new BSE reference 
limits for left and right heart parameters, combined 
with explanations of the methodology, decision-making 
process, and discussions regarding the potential clinical 
impact of the new reference intervals. Where appropriate, 
we have described the methodology by which some of 
the measurements should be acquired, but for a more 
detailed description regarding the echocardiographic 
measurements and how they should be obtained, please 
see the BSE minimum dataset (28).
Left ventricular linear dimensions and LV mass
New reference intervals for linear LV dimensions and 
LV mass are presented in Table 2. LV dimensions should 
be obtained from the parasternal long-axis (PLAX) 
window preferentially using 2D imaging. The BSE would 
discourage the use of M-mode measurements as routine, 
although they are acceptable if the long-axis of the left 
ventricle is perpendicular to the angle of incidence of 
the ultrasound beam. LV mass should be calculated using 
the linear method from 2D imaging and reported after 
indexing to BSA (8).
The BSE has chosen to publish an upper reference 
limit only for wall thickness measures with no separate 
Table 2 Linear left ventricular dimensions and mass.
Normal Mild Moderate Severe
Males
 LV dimensions
  LVIDd (mm) 37–56 57–61 61–65 >65
  LVIDs (mm) 22–41 41–45 46–50 >50
  IVSd (mm) 6–12 – – –
  LVPWd (mm) 6–12 – – –
 LV mass     
  LVMi (g/m2) 40–110 111–127 128–145 >145
  LV mass (g) 72–219 – – –
Females
 LV dimension
  LVIDd (mm) 35–51 52–55 56–59 >59
  LVIDs (mm) 20–37 38–42 43–46 >46
  IVSd (mm) 5–11 – – –
  LVPWd (mm) 6–12 – – –
 LV mass     
  LVMi (g/m2) 33–99 98–115 116–131 >131
  LV mass (g) 51–173 – – –
IVSd, inter-ventricular septal thickness in diastole; LV, mass calculated using 
the linear method; LVIDd, left ventricular internal diameter in diastole; LVIDs, 
left ventricular internal diameter in systole; LVMi, left ventricular mass index; 
LVPWd, left ventricular posterior wall thickness in diastole.
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partitions for mild, moderate, or severe changes, as using 
standard deviations to define partitions would result 
in such narrow ranges that they would be clinically 
meaningless.
LV wall thickness by itself does not define an individual 
as having left ventricular hypertrophy (LVH). Rather, the 
presence or absence of LVH is determined from LV mass 
after indexing to BSA. Wall thickness measurements, 
combined with the LV internal diameter in diastole, can 
be used to determine the relative wall thickness (RWT) 
using the following formula:
RWT
IVSd LVPWd
LVIDd
=
+
The combination of indexed LV mass and relative wall 
thickness can be used to define LV geometry (Fig. 2). In the 
context of an increased mass, an RWT > 0.42 defines the 
pattern of LVH as being ‘concentric’. If the RWT is ≤0.42, 
the pattern of LVH is ‘eccentric’. The pattern of LVH 
provides an insight into the underlying pathophysiological 
state. Concentric LVH is characteristically seen in 
patients with increased afterload such as aortic stenosis 
or hypertension. Eccentric LVH is more likely to be seen 
in scenarios with increased LV pre-load and associated 
compensatory hypertrophy, such as chronic aortic 
regurgitation (AR) or mitral regurgitation (MR).
A common misconception is that concentric LVH is 
synonymous with uniform thickening of the myocardial 
walls. It is possible to have localised or focal areas of 
increased wall thickness in patients with concentric LVH, 
just as there may be uniform thickening of muscle in 
patients with eccentric LVH.
If LV mass is normal (i.e. the patient does not have 
LVH), an RWT > 0.42 demonstrates the presence of 
‘concentric remodelling’. This can be thought of as a pre-
hypertrophy state and may help to identify individuals 
who would benefit from identification and optimization 
of risk factors (i.e. hypertension) (6).
Left ventricular volumes
Reference intervals for LV volumes are presented in 
Table 3. Left ventricular volumes should be obtained using 
2D imaging from the apical 4- and 2-chamber windows 
using the biplane Simpson’s method. When obtaining LV 
volumes using the biplane method, care should be taken 
to ensure that the apical 4- and 2-chamber windows are 
separated by 60° of rotation (and not 90° as is sometimes 
assumed). In addition, it is paramount that the LV is not 
foreshortened. Volumes should be reported after indexing 
to BSA.
Figure 2
LV geometry determined by indexed LV mass and relative wall thickness.
Table 3 Left ventricular volumes.
Normal
Mildly 
dilated
Moderately 
dilated
Severely 
dilated
Males
 LVEDVi (mL/m2) 30–79 80–91 92–103 >103
 LVESVi (mL/m2)  9–31 32–36 37–42 >42
 LVEDV (mL) 53–156 – – –
 LVESV (mL) 15–62 – – –
Females
 LVEDVi (mL/m2) 29–70 71–81 82–91 >91
 LVESVi (mL/m2)  8–27 28–32 33–37 >37
 LVEDV (mL) 46–121 – – –
 LVESV (mL) 13–47 – – –
Volumes obtained using the biplane Simpson’s method.
LVEDV(i), left ventricular end-diastolic volume (indexed); LVESV(i), left 
ventricular end-systolic volume (indexed).
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Left ventricular ejection fraction
Summary
 • Reference intervals for LVEF are the same for males and 
females (Table 4).
 • LVEF should be derived from 2D volume data using the 
biplane Simpson’s method.
 • Normal LVEF is defined as an EF ≥55%.
 • Patients with an LVEF between 50 and 54% are defined 
as having ‘borderline low LVEF’.
 • Patients with an LVEF between 36 and 49% are defined 
as having ‘impaired LVEF’. The BSE discourages use of 
the terms ‘mild’ or ‘moderate’.
 • These reference intervals do not apply to values of LVEF 
obtained using 3D imaging. If EF is obtained using 3D 
imaging, these should be compared to vendor-specific 
reference intervals.
Rationale and discussion
LVEF should be derived using the biplane Simpson’s 
method from 2D volumes, obtained from the apical 4- 
and 2-chamber views as described above. It is essential 
that values for LVEF are not derived from foreshortened 
or poorly obtained volumetric data. The BSE has chosen 
to keep reference intervals the same for males and females 
(Table 4).
Within the NORRE dataset, there was a statistically 
significant difference between males and females with 
regards to ejection fraction values (8). For males, the lower 
reference limit was 53.5%, whereas for females, the value 
was 54.5%. The P value for the difference between men 
and women was 0.009. Despite the statistical difference 
between genders, the absolute difference is so small as 
to be clinically insignificant. It would be very unusual 
to report echocardiographic-derived EF values with 
a purported accuracy of 1%: accepted inter-operator 
variability of LVEF measurements are often in the order 
of 5%. Additionally, for men and women alike, there was 
a statistically significant increase in LVEF with aging: for 
women under 40 years of age, the lower reference limit 
was 53.9%, whereas for women over 60 years of age, 
this limit was 55.1%. Again, for practical purposes, these 
differences are clinically insignificant.
Given this, the BSE chose to keep LVEF reference 
intervals the same for men and women, with normal LVEF 
defined as a value ≥55%.
The BSE chose to define ‘severely impaired LVEF’ 
as an LVEF ≤35% for both males and females. This is 
in contrast to the joint ASE/EACVI guidance, which 
classifies ‘severely abnormal LVEF’ as <30% (5, 6). 
The rationale for the BSE decision is one of clinical 
utility. There is a large body of evidence demonstrating 
that therapeutic drugs used in the management of left 
ventricular systolic dysfunction are of prognostic value 
when LVEF is ≤35%. This includes ACE-inhibitors, 
B-blockers, mineralocorticoid receptor antagonists, 
angiotensin receptor antagonists, If-channel inhibitors, 
and angiotensin receptor-neprilysin inhibitors (29, 
30, 31, 32, 33, 34, 35, 36, 37, 38). Furthermore, in UK 
practice, device therapy for heart failure, including CRT 
and ICD, are also indicated when the LVEF is 35% or 
below (38, 39, 40, 41). Although it is true to state that 
a lower ejection fraction is associated with a poorer 
prognosis (13), there are no additional therapeutic 
interventions either mandated or available only after 
LVEF falls below 30%. For these reasons, in the opinion of 
the BSE, the most useful threshold for severely impaired 
LVEF is ≤35% as this provides clarity for clinicians and 
sonographers alike.
A change is also advocated for LVEF values between 35 
and 55%. The BSE has chosen to depart from the tradition 
of splitting this group into ‘mild’ or ‘moderate’ bands and 
have defined individuals with an EF between 50 and 54% 
as ‘borderline low LVEF’, and those patients with values 
between 36 and 49% as ‘impaired LVEF’. The rationale for 
this approach is as follows.
As outlined in the ‘defining reference limits’ section, 
the method by which the LRL for LVEF is calculated 
means that 2.3% of normal individuals will fall below 
the threshold and may consequently (and incorrectly) 
be labelled as having LV systolic impairment. This can 
have important consequences upon that individual: 
for example, with regards obtaining life insurance, or 
impacting career decisions. However, it is also true to state 
that within this cohort there are patients whose prognosis 
is constrained (42). Too much emphasis has been placed 
on LVEF as the sole arbiter of normal systolic function. 
Just as no one parameter defines diastolic function, LVEF 
similarly cannot provide a binary normal/abnormal 
cut off for systolic function. The BSE has therefore 
highlighted that patients with an EF between 50 and 
54% have ‘borderline low LVEF’. The sonographer and 
Table 4 Left ventricular ejection fraction.
Severely 
impaired 
LVEF
Impaired 
LVEF
Borderline 
low LVEF
Normal 
LVEF
Males and females
 LVEF (%) ≤35% 36–49% 50–54% ≥55%
LVEF derived using the biplane Simpson’s method.
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clinician require more information before labelling such 
a patient as having normal or abnormal systolic function. 
This is akin to the traffic light system advocated for MRI 
reference intervals derived from the UK biobank cohort 
(43). Additional information to help determine whether 
a patient is normal may include LV volumes and tissue 
Doppler imaging (s′ and e′), prior echo reports, clinical 
history, cardiovascular symptoms, family history, and a 
functional assessment. Recommending repeating the 
echo after a 6–12-month interval may be required.
Once LVEF falls below 50%, this corresponds to 
three standard deviations below the mean. It is therefore 
exceptionally unlikely that a normal individual would 
have an EF below this value (fewer than 0.15% of the 
normal population). As such, those patients with values 
between 36 and 49% should all be classed as having 
‘impaired LVEF’ and the ejection fraction quoted. All 
patients within the ‘impaired LVEF’ cohort have reduced 
left ventricular systolic function and such a finding 
should prompt a comprehensive clinical assessment and 
discussion with the patient.
An LVEF of 50% has important implications in both 
heart failure and valvular heart disease management, 
re-enforcing the use of this threshold as a clinically 
relevant cut-off. When the LVEF is below 50%, there 
remains a reasonable body of evidence that therapeutic 
agents may be of value in improving survival (44, 45, 
46). Similarly, observational data have suggested that 
cardiovascular survival and outcomes are significantly 
poorer once LVEF is lower than 50% (42). A cut-off for 
LVEF of 50% therefore ensures that all individuals who 
may benefit from heart failure therapy are included in 
the ‘impaired LVEF’ group. This range is similar to that 
proposed by the European Society of Cardiology who 
have defined a ‘heart failure with mid-range ejection 
fraction’ group in whom it is reasonable to consider 
medical therapy whilst accepting that further research 
is required (38, 47). Conversely, even in patients with 
clinical heart failure and LVEF values of >50% (heart 
failure with preserved ejection fraction; HFpEF), there is 
no evidence to support that routine use of heart failure 
medications improves survival (38).
The BSE discourages use of the terms ‘mild’ or 
‘moderate’ reduction in LVEF.
Previously, inter-observer variation would often result 
in patients alternating between the mild and moderate 
categories without this having any clinical meaning. 
The current methodology will hopefully allow more 
consistency with regards reporting within the range of 
LVEF between 36 and 49%.
With regards 3D volumetric assessment and 3D-derived 
ejection fraction, the BSE stresses that reference intervals 
for 2D-derived ejection fraction do not apply to 3D results: 
for example, an ejection fraction of 56% derived using 3D 
software is not necessarily normal, and comparison with 
vendor-specific reference intervals should be used.
Left atrial size
Summary
 • Reference limits for LA volume are the same for males 
and females.
 • LA volume should be obtained from apical 4- and 
2-chamber windows using the biplane Simpson’s 
method and indexed for BSA.
 • An LA volume index (LAVi) of <34 mL/m2 is normal.
 • An LAVi between 34 and 38 mL/m2 is a borderline 
result.
 • An LAVi of >38 mL/m2 is abnormal.
 • The area-length (A-L) method should not be used 
interchangeably with the Simpson’s method. BSE 
reference intervals for LA volume do not apply to values 
obtained using the A-L method.
 • Routine use of linear LA dimensions is not encouraged, 
but may be used in some clinical scenarios.
Rationale and discussion
Reference limits for left atrial size are presented in 
Table  5. LA volume should be obtained from apical 4- 
and 2-chamber windows (separated by 60° of rotation), 
optimised for LA assessment, using the biplane Simpson’s 
method. Maximal LA volume should be obtained from the 
frame immediately prior to mitral valve opening. Values 
should be reported after indexing for BSA.
Although absolute LA volumes are usually larger in 
males than females, this difference is entirely neutralised 
when indexing for BSA. As such, routine assessment of 
indexed LA volumes allows a single reference limit for both 
males and females to be utilized (8). Indexed LA volumes 
are linked to adverse prognosis and poor cardiovascular 
outcomes, supporting the routine use of this measure in 
patients (15, 16, 48, 49, 50, 51, 52).
Table 5 LA volume.
Normal Borderline Dilated
Males and females
 LAVi (ml/m2) <34 34–38 >38
LA volume obtained using biplane Simpson’s method.
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There were two particularly interesting observations 
reported within the NORRE dataset. Firstly, the NORRE 
investigators examined two widely used but differing 
methods to assess LA volume on all included subjects: 
the biplane method of discs (Simpson’s method) and 
the biplane area-length method. Consistent with earlier 
comparative studies of these two methods, NORRE 
demonstrated that the area-length technique produces 
values for LA volume systematically larger than those 
obtained using the Simpson’s method (8, 53). Given this, 
it is evident that these two methodological approaches to 
the assessment of LA volume are not inter-changeable as 
is often assumed, and different reference limits should be 
applied to each.
Unfortunately, this observation creates a number 
of potential conflicts in echocardiographic practice, as 
previous guidelines from the ASE, EACVI and BSE have not 
differentiated between these two methods. For example, 
when assessing for diastolic dysfunction, an LAVi of >34 
mL/m2 is one marker for the presence of elevated filling 
pressures (54). It is possible, therefore, that an individual 
could have an LAVi above this limit if the area-length 
method were used, but below this limit if the Simpson’s 
method were chosen.
The second interesting observation from NORRE 
is that LA volumes in the normal population were 
significantly larger than previous work has suggested, 
which appears to conflict with the published association 
between increased LA volumes and poor prognosis. From 
the NORRE data, the upper reference limit for LAVi using 
the Simpson’s method is 38 mL/m2 and using the area-
length method it is 42 mL/m2. For comparison, in previous 
observational work of unselected patients, an LAVi of 
>40 mL/m2 (obtained using the area-length method) is 
associated with considerably poorer survival. Even those 
subjects with an LAVi of >34 mL/m2 have significantly 
worse outcomes (16).
The explanation for this discrepancy is not clear. 
Although it is well recognized that athletes can develop 
enlarged atria, the NORRE protocol excluded such 
individuals from the study (7, 24, 55). Nor does it seem 
likely that undiagnosed diastolic dysfunction is an 
explanation: the proportion of individuals with an LAVi 
of >34 mL/m2 was similar across the age categories.
Given the robust nature of patient inclusion and echo 
analysis, the NORRE results are compelling and strongly 
suggest that the range of normality for LA volume is larger 
than previously thought. The results also suggest that 
there is a substantial overlap between physiological and 
pathophysiological LA remodelling.
The BSE has chosen to advocate a compromise 
approach that acknowledges the results of NORRE, 
but also ensures that an LA volume sufficient for identifying 
patients with diastolic dysfunction is highlighted.
A consensus view was therefore achieved within 
the writing committee. Using the biplane Simpson’s 
method, normal LAVi is ≤34 mL/m2. Values between 34 
and 38 mL/m2 should be considered ‘borderline’: as an 
isolated finding such a result is normal. In the presence 
of additional indicators for diastolic dysfunction, for 
example, an elevated E/e′, an LAVi within this range 
should be considered a marker of elevated filling pressures. 
An LAVi of more than 38 mL/m2 is enlarged.
Finally, the BSE does not advocate the routine use of 
linear LA dimensions, although left atrial diameter may 
still be used in some clinical scenarios, including risk-
assessment in hypertrophic cardiomyopathy (56).
The right heart
Summary
 • The BSE advocates the routine use of indexed right 
ventricular end-diastolic (RVED) area, and indexed 
RA area.
 • Conventional linear measurements including RV basal 
diameter (RVD1) and right ventricular outflow tract 
diameter (RVOT) should additionally be obtained in 
all patients.
 • Updated reference limits for linear dimensions are 
substantially different from previous BSE guidance and 
contemporary joint ASE/EACVI guidelines.
Rationale and discussion
For the first time, the BSE is advocating use of indexed 
parameters in the routine assessment of both right 
ventricular (RV) and right atrial (RA) size. These parameters 
are the indexed right ventricular end-diastolic (RVED) 
area (Fig. 3) and the indexed RA area. This proposed 
methodology acknowledges that the right heart varies 
according to body habitus and brings echocardiographic 
reporting of right heart size more in keeping with the 
accepted method of reporting left heart chamber size. These 
newer measures should be combined with conventional 
linear assessment in all patients. Conventional measures 
include the RV outflow tract (RVOT) dimensions, obtained 
from the parasternal short axis (PSAX) window (Fig. 4), and 
RV body dimensions (Fig.  5), which should be obtained 
from the RV-focussed view. Remember that the RV-focussed 
view is not necessarily the same as the standard 4-chamber 
view, but is adjusted such that the diameter of the RV is 
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maximised, whilst keeping the imaging plane through the 
centre of the LV cavity (4).
Reference limits for right heart measurements and 
fractional area change (FAC) are presented in Table 6.
The anatomy of the right heart, and RV in particular, 
is complex. All three components of the RV cannot be 
visualised from a single echocardiographic plane and 
therefore it is imperative that sonographers do not rely 
on a single measure to define the presence or absence 
of RV enlargement. Moreover, in some patients there 
can be relative enlargement of one RV component 
(for example, the outflow tract), whereas the main body 
of the RV may be normal. To account for this complexity, 
the BSE suggests that indexed RVED area is combined 
with basal RV dimensions and an assessment of RVOT size 
in all patients.
The BSE accepts that routine indexing of right heart 
parameters is not yet widespread, and indeed these 
measurements are not included within the BSE minimum 
dataset (28). However, indexed parameters account for 
both gender and body habitus and are physiologically 
more robust. The NORRE study obtained indexed right 
Figure 3
Assessment of RV size and fractional area change 
(FAC). From the RV-focussed apical 4-chamber 
window, a contour should be traced from the 
lateral tricuspid annulus along the free wall to the 
apex, and back along the interventricular septum 
to the medial tricuspid valve annulus. This should 
be undertaken at end-diastole (left panel), and the 
area indexed to BSA, providing us with indexed 
RV end-diastolic area. This process can be 
repeated in end-systole (right panel), from which 
we can derive the FAC as follows: FAC = (RVA 
diastole − RVA systole)/RVA diastole × 100%.
Figure 4
RVOT assessment (RVOT1). From the PSAX window, and in end-diastole, 
measurement should be made from the anterior aortic wall directly up to 
the RVOT free wall (at the level of the aortic valve). The PSAX view is more 
reproducible than RVOT PLAX.
Figure 5
RV body measurements. All measurements should be obtained at 
end-diastole in the RV-focused apical 4-chamber view. RVD1: Basal RV 
diameter. Measured at the maximal transverse diameter in the basal one 
third of the RV. RVD2: Mid RV diameter measured at the level of the LV 
papillary muscles. RVD3: RV length, from the plane of the tricuspid 
annulus to the RV apex.
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heart parameters within its dataset, from which the 
BSE propose an upper reference limit for indexed RVED 
area of 13.6 cm2/m2 (males) and 12.6 cm2/m2 (females), 
with an upper reference limit for indexed RA area of 11 
cm2/m2 for both men and women.
A potential limitation of indexed right heart area 
parameters is that the inter-observer variability is inferior 
to conventional linear measurements (8). For this reason, 
the BSE advocates that the indexed area is combined with 
conventional linear measures in all patients.
Reference limits for linear dimensions have also been 
updated using the NORRE data. With regards the RV basal 
diameter (RVD1), the BSE defines the upper reference limit 
for males as 47 mm, whereas for females the URL is 43 
mm. These values are larger than the currently published 
reference limit of 41 mm for both men and women. The ASE 
defined the current value in 2010, using pooled data from 
10 studies, including a combined total of 376 individuals 
(4). The most contemporaneous joint American and 
European guidance derived most right heart dimensions 
from fewer than 700 subjects (5, 6). The NORRE dataset 
by itself includes more than 700 individuals, in addition 
to having the benefits of consistency of inclusion and 
analysis outlined previously. Furthermore, the ASE/
EACVI upper reference limit for RV size is universal (i.e. 
the same for both males and females), thereby suggesting 
that gender (and by inference, BSA) does not influence 
RV size, which seems fundamentally unlikely. The 2010 
ASE guidance published a range of potential values for 
the upper reference limit, acknowledging that there is a 
degree of uncertainty in any statistical modelling (4). This 
range was 39–45 mm, and 41 mm was the mid-point of 
this range. Using NORRE the combined URL for men and 
women was 43.7 mm, which falls within this previously 
published range, confirming that the current values are 
not dramatically different from what may have been 
expected.
The upper reference limit for the RV mid-point 
diameter is now 42 mm (males) and 35 mm (females). 
Again, these are slightly larger than the previous 
guidance, but for all the reasons outlined above, there is 
no fundamental conflict with previously published data.
The RVOT should be measured using 2D imaging from 
the PSAX window. Using the NORRE dataset, the upper 
reference limits for the RVOT demonstrate substantial 
differences from previously accepted guidelines: in males 
the URL is 44 mm, whereas for females it is 42 mm. This 
is larger than previously described, when the universal 
cut-off for both men and women was 35 mm. It is not 
immediately apparent why the current results appear to 
be larger than earlier work had suggested. For the distal 
RVOT, the current reference limits are very similar to 
previously published guidance.
RV fractional area change is a useful tool to assess RV 
function. NORRE demonstrated that there is a significant 
difference between men and women with regards values 
for FAC: for males the lower reference limit is 30% whereas 
for females it is 35%.
Clinical implications
Two potential clinical impacts of the new reference 
intervals for the right heart are in the echocardiographic 
assessment of pulmonary hypertension (PH) and 
arrhythmogenic right ventricular cardiomyopathy 
(ARVC).
A major criterion for the diagnosis of ARVC is the 
presence of regional RV wall motion abnormalities, 
combined either with impaired RV function (defined 
as an FAC of ≤33%), or an enlarged RV. This latter was 
Table 6 Right heart parameters.
Normal
Males
 Indexed values  
  RVED area (cm2/m2) ≤13.6
  RA area (cm2/m2) ≤11
 Absolute values
  RVOT proximal (mm) 24–44
  RVOT distal (mm) 16–29
  RVD1 (mm) 26–47
  RVD2 (mm) 19–42
  RVD3 (mm) 55–87
  RA area (cm2) ≤22
 Right heart function
  FAC (%) ≥30
Females
 Indexed values
  RVED area (cm2/m2) ≤12.6
  RA area (cm2/m2) ≤11
 Absolute values
  RVOT proximal (mm) 20–42
  RVOT distal (mm) 14–28
  RVD1 (mm) 22–43
  RVD2 (mm) 17–35
  RVD3 (mm) 51–80
  RA area (cm2) ≤19
 Right heart function
  FAC (%) ≥35
FAC, fractional area change; RA, right atrial; RVD1, right ventricular basal 
diameter in diastole; RVD2, right ventricular mid-point diameter in diastole; 
RVD3, right ventricular length in diastole; RVED, right ventricular end-
diastolic area, obtained from the RV-optimised apical 4-chamber view; 
RVOT distal, right ventricular outflow tract at the level of the pulmonary 
valve from the parasternal short axis window; RVOT proximal, proximal 
right ventricular outflow tract obtained from the parasternal short 
axis view.
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defined as an RVOT proximal diameter of ≥36 mm 
measured from the PSAX window (57). It appears 
challenging to rationalize this major criterion with the 
new reference intervals for the RV. However, size of the 
RVOT in and of itself is not sufficient to qualify as a major 
criterion for the diagnosis of ARVC. Regional wall motion 
abnormalities of the RV are the pre-requisite finding, and 
only when these are seen does size subsequently play a 
role. Similarly, minor criteria for the diagnosis of ARVC 
include an RVOT diameter of between 32 and 36 mm 
or a fractional change of ≤40% (both in the context of 
regional abnormalities of RV contractility). These minor 
criteria for RVOT dimensions and RV function both fall 
within the previously published reference limits. The 
apparent conflict between the current reference intervals 
and diagnosis of ARVC is therefore not new.
With regards pulmonary hypertension, recent guidance 
by the BSE mirrors earlier work from the EACVI (58, 59). The 
principle of the PH guidance is to quantify the likelihood 
of pulmonary hypertension being present, rather that 
reporting absolute values of pulmonary artery (PA) pressure. 
The probability of PH is based primarily upon the tricuspid 
regurgitation (TR) maximal velocity, although the presence 
of two additional echo characteristics can subsequently 
increase the likelihood of pulmonary hypertension being 
present. Most of these additional echo characteristics are 
unaffected by the new right heart reference limits. The 
exception is a right atrial area of >18 cm2, which would 
now be defined as a normal finding within the current 
reference intervals for both males and females.
We believe that this guideline change is exceptionally 
unlikely to affect clinical practice. According to the 
NORRE data, fewer than 5% of males, and an estimated 
3% of normal females would be expected to have an 
RA area of >18 cm2. In these individuals, it would need 
further supportive echo evidence of PH to potentially 
alter the overall likelihood of pulmonary hypertension 
being present. These additional echo characteristics are 
also very unlikely to occur in normal individuals: for 
example, a pulmonary acceleration time of <105 ms 
would be expected to occur in fewer than 2.5% of normal 
patients. Therefore, the combined probability of both an 
RA area >18 cm2 and a pulmonary acceleration time <105 
ms occurring by chance in a normal individual is less than 
1 in 1000.
Although the reference intervals for linear right heart 
dimensions do vary from historic guidance, this likely 
reflects that the source of previous data was somewhat 
limited, and NORRE has substantially increased our 
understanding of normal right heart chamber dimensions. 
Remember, even though the upper limit for RV size has 
now increased, if the RV is seen to be larger than the left 
ventricle, this should prompt further consideration.
Aortic dimensions
Summary
 • Aortic dimensions should be measured using 2D 
imaging from the PLAX window.
 • Indices should be obtained using the inner-edge 
to inner-edge (IE-IE) methodology in end-diastole, 
defined as the onset of the QRS complex.
 • All values should be indexed to height and not BSA.
 • For those echo labs that currently employ the leading-
edge to leading-edge (LE-LE) technique, it is reasonable 
to continue doing so for continuity and consistency.
 • The BSE suggests that echo labs include the method 
of assessment within the echo report to ensure 
transparency for clinicians.
Rationale and discussion
Reference limits for the recommended measurements for 
aortic root dimensions are presented in Table 7. Aortic 
dimensions should be obtained using the IE-IE technique 
in end-diastole, defined as the onset of the QRS complex 
(Fig. 6). Aortic indices should be indexed for height and 
not BSA as was previously recommended.
Historical measurements of aortic root size used the 
LE-LE methodology owing to the poor resolution available 
at the time. This dimension is neither the outer nor the 
inner size of the aorta, but has resulted in reference values 
and cut-offs for therapy (such as aortic root replacement) 
that are embedded in contemporary guidance (60). 
Conversely, there is evidence that measurements of 
the aortic root using the IE-IE methodology is more 
readily obtained and more reproducible (61). Previous 
BSE guidance has advocated the IE-IE technique, and 
therefore, to maintain consistency, the current guidance 
advises ongoing use of this approach. The BSE suggests 
that echo labs document how aortic root dimensions are 
Table 7 Normal indexed aortic root dimensions.
Male Female
Sinus of Valsalva (mm/m) 13.8–21.8 13.1–20.7
Sino-tubular junction (mm/m) 11.4–18.6 11.0–17.8
Proximal ascending aorta (mm/m) 11.5–19.9 11.4–19.8
Inner edge to inner edge methodology; indexed to height; obtained in end-
diastole (onset of QRS). Proximal ascending aorta measures obtained 1 cm 
above the sino-tubular junction.
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obtained within echo reports, particularly if a decision has 
been made to alter the methodological approach.
On average, aortic dimensions are 1.2 mm smaller 
when using IE-IE compared to LE-LE. The BSE believes 
that this is unlikely to have a significant impact on 
clinical decision-making: patients who are close to the 
cut-off for surgery invariably undergo additional imaging 
such as CT or MRI. These modalities can confirm the true 
maximal aortic size, but also have the advantage of being 
able to visualise the entire aorta (a necessary step before 
surgery) and obtain a true co-axial slice through the aorta. 
CT also has the potential to obtain information on the 
coronary arteries, which may avoid the need for invasive 
angiography.
The aorta should be measured at end-diastole, as 
this measurement is more reproducible, at least in part 
owing to the clear timing reference, whereas mid-systole 
is less easy to define (61). This will make echo surveillance 
with sequential measurements of a dilating aorta more 
reproducible. Aortic dimensions obtained in diastole are 
consistently smaller than corresponding measurements 
made in systole (10, 61). If the aorta in question is 
approaching the point at which intervention is required, 
the BSE suggests that corroborative measurements are 
made with an additional imaging modality.
Traditionally, nomograms have been used to present 
reference intervals in a visually appealing way as it 
varies against a dependent variable, such as BSA. The 
aortic root diameter has been compared against three 
age-specific nomograms derived from a single paper by 
Roman  et al. (62). Despite the authors’ recommending 
the use of their nomogram for children only, the adult 
versions have been included in virtually all chamber 
guidelines and textbooks ever since (5, 6, 63, 64). These 
adult nomograms have some limitations: small sample 
size, poorly defined ‘normal’ subjects, bias to BSA (which 
is adversely affected by obesity), and finally a sharp jump 
in results when the subject turns 40 owing to a change 
in the equation used. These problems have been well 
described elsewhere (65).
In the subsequent 25 years, many studies have 
attempted to improve on this. Devereux   et  al. have 
derived equations for aortic root dimensions from 1207 
apparently normal subjects (66). However, the data were 
derived from a mixture of studies, including the original 
Roman group. The methodology was not pre-specified, 
with the aortic root occasionally measured from the 
apical three-chamber view, which is not used routinely in 
practice and is unlikely to be comparable to results from 
the parasternal long-axis window.
The NORRE dataset obtained data for normal aortic 
root values at four different levels, including the Sinus 
of Valsalva, the ST-junction, and the proximal ascending 
aorta (also referred to as the tubular ascending aorta) using 
both LE-LE and the IE-IE methodology. Additionally, 
NORRE obtained data for aortic dimensions both in 
end-diastole (defined as the onset of the QRS complex) 
and mid-systole, which corresponds to maximal aortic 
dimensions (10). Consequently, there is a vast array of 
data from which reference limits can be derived.
NORRE, along with earlier work by Oxborough  et al., 
demonstrated that aortic root dimensions are best 
correlated to height and not BSA (10, 61). This is a change 
from the currently accepted practice and will have 
potential benefits in overweight individuals. Indexing to 
height also results in similar reference limits for younger 
and older individuals alike and therefore greatly simplifies 
the reference intervals.
Figure 6
Assessment of aortic root dimensions. The measurements should be 
obtained using the inner-edge to inner-edge methodology in end diastole 
(defined as the onset of the QRS). Measurements should be obtained at 
three levels including: sinus of Valsalva (red line); sino-tubular junction 
(green line); proximal ascending aorta defined as the region 1 cm above 
the sino-tubular junction (blue line). If there is enlargement above this 
level the maximal dimension should be measured and stated in report. 
Measurements should be reported after indexing for height.
Table 8 Normal indexed aortic root dimensions (leading 
edge-leading edge methodology).
Male Female
Sinus of Valsalva (mm/m) 14.8–23.2 14.1–22.1
Sino-tubular junction (mm/m) 12.6–19.8 12.2–19.4
Proximal ascending aorta (mm/m) 12.6–21.4 12.3–21.1
Leading edge to leading edge methodology; indexed to height; obtained in 
end-diastole (onset of QRS). Proximal ascending aorta measures obtained 
1 cm above the sino-tubular junction.
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For those echo departments currently utilising the 
LE-LE methodology, it is reasonable to continue this 
practice for consistency. New reference limits for the 
LE-LE methodology are presented in Table 8.
Tissue Doppler imaging
Tissue Doppler imaging (TDI) is a useful technique that 
is both robust and reproducible. Values for the left heart 
should be obtained as the average of medial and lateral 
mitral annular systolic velocities, and obtained during a 
breath hold in end-expiration. Values are similar for both 
men and women, but vary according to age (Table 9).
Right ventricular TDI values should be obtained from 
the lateral RV annulus. RV indices are similar for males 
and females and do not vary significantly according to 
age (Table 9).
Strain values
The BSE has chosen not to include reference limits for strain 
parameters. Unfortunately, there is still significant inter-
vendor variability, such that a single reference interval 
would not suffice for all practitioners. Additionally, it is 
not clear whether different versions of strain software give 
comparable results. Individual vendors currently provide 
reference intervals for specific platforms and software 
versions.
Despite this, strain imaging is more widespread and 
has increasing clinical utility in echocardiographic practice. 
Strain tools are of value when used sequentially on a single 
individual in order to help identify whether there have been 
subclinical changes in LV performance. Such an example 
would be when monitoring the effect of chemotherapy on 
LV systolic function (67). Given the current vendor- and 
even software-version variations in strain, it is important 
that this is documented in the report and every effort made 
to provide continuity between assessments. If a vendor’s 
measurement tools are upgraded, old studies should be 
re-measured before they are used for comparison.
Summary
The BSE believe that the current guidance provides robust 
reference intervals for use in day-to-day practice in UK 
echo labs. This report contains guidance only and should 
also be used in conjunction with clinical assessment and 
interpretation. The reference intervals within should not 
be used as the sole reason for making clinical decisions for 
individual patients.
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